Loading market dashboard
Newron Pharmaceuticals S.p.A.
NWPHFHealthcareOTCIT
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #Biotech--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that Stefan Weber, CEO and Roberto Galli, CFO, will participate in the following investor conferences in June: Jefferies Global Healthcare Conference, June 2–4, 2026, New York H.C. Wainwright 7th Annual Neuro Perspectives.
Newron Pharmaceuticals S.p.A. (NWPHF) Q4 2025 Earnings Call Transcript
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron today announced its financial results and operational highlights for the business year ended Dec. 31, 2025, and provided an outlook for 2026.
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it will take part in a workshop and present three posters at the upcoming SIRS 2026 Annual Congress taking place March 25-29, 2026, at the exhibition and congress area Firenze Fiera in Florence, Italy. Workshop Wednesday,.
